Search

Your search keyword '"Summers Y."' showing total 238 results

Search Constraints

Start Over You searched for: Author "Summers Y." Remove constraint Author: "Summers Y."
238 results on '"Summers Y."'

Search Results

1. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

2. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

6. Body composition and lung cancer-associated cachexia in TRACERx

7. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

8. Genomic–transcriptomic evolution in lung cancer and metastasis

9. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

10. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

11. The evolution of lung cancer and impact of subclonal selection in TRACERx

12. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

13. MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J

14. PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma

16. The evolution of lung cancer and impact of subclonal selection in TRACERx

17. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations

18. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations

21. 115P Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)

22. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

23. 108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes

25. Pneumocystis jirovecii pneumonia (PJP) prophylaxis in lung cancer patients receiving radical radiotherapy (RT) ± chemotherapy (CTRT): audit of the first UK departmental guideline

28. PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

30. Brigatinib experience on the ALK project

32. The ALK project: a real-world national network and database

34. Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study

35. Multi-modality radical intent treatment in synchronous oligometastatic non-small cell lung cancer: how many patients complete the full treatment regime recommended by the MDT?

37. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

38. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

39. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

40. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

41. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial

43. Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial

44. P1.01-26 Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials

46. P2.13-01 Brigatinib Use in England – Where Next?

48. Single institution analysis of pneumocystis jirovecii pneumonia in patients undergoing treatment for lung cancer: recommendations for PJP prophylaxis

49. Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement

50. Treatment pathways in small cell lung cancer (SCLC) in the Greater Manchester (GM) network- an analysis of timeliness of therapy and impact on survival

Catalog

Books, media, physical & digital resources